Collegium Pharmaceutical (NASDAQ:COLL) Lifted to Buy at ValuEngine

ValuEngine upgraded shares of Collegium Pharmaceutical (NASDAQ:COLL) from a hold rating to a buy rating in a research note issued to investors on Thursday morning, ValuEngine reports.

Several other equities analysts have also recently weighed in on COLL. Needham & Company LLC reduced their price target on Collegium Pharmaceutical from $33.00 to $25.00 and set a buy rating for the company in a research report on Wednesday, October 30th. Cantor Fitzgerald reiterated an overweight rating and issued a $24.00 price target (down from $35.00) on shares of Collegium Pharmaceutical in a research report on Thursday, August 8th. Jefferies Financial Group lifted their price target on Collegium Pharmaceutical from $26.00 to $36.00 in a research report on Thursday, November 7th. BidaskClub upgraded Collegium Pharmaceutical from a hold rating to a buy rating in a research report on Wednesday, November 6th. Finally, Zacks Investment Research cut Collegium Pharmaceutical from a hold rating to a sell rating in a research report on Thursday, November 7th. One investment analyst has rated the stock with a sell rating and eight have issued a buy rating to the company. The company presently has an average rating of Buy and a consensus target price of $24.57.

NASDAQ:COLL traded up $0.75 during trading hours on Thursday, reaching $18.86. The stock had a trading volume of 302,600 shares, compared to its average volume of 380,309. The company has a debt-to-equity ratio of 0.22, a quick ratio of 1.20 and a current ratio of 1.24. The stock has a 50 day simple moving average of $13.50 and a 200 day simple moving average of $12.26. Collegium Pharmaceutical has a 12-month low of $10.01 and a 12-month high of $19.99. The stock has a market cap of $613.21 million, a P/E ratio of -15.85 and a beta of 0.52.

Collegium Pharmaceutical (NASDAQ:COLL) last released its earnings results on Wednesday, November 6th. The specialty pharmaceutical company reported ($0.18) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.15) by ($0.03). Collegium Pharmaceutical had a negative return on equity of 13.14% and a negative net margin of 3.86%. The firm had revenue of $72.94 million during the quarter, compared to analysts’ expectations of $74.32 million. During the same period in the prior year, the business earned ($0.50) earnings per share. The business’s quarterly revenue was up 3.9% compared to the same quarter last year. On average, equities analysts expect that Collegium Pharmaceutical will post -0.64 earnings per share for the current fiscal year.

In other news, Director David Hirsch sold 22,106 shares of Collegium Pharmaceutical stock in a transaction on Thursday, August 29th. The stock was sold at an average price of $11.65, for a total value of $257,534.90. Following the completion of the transaction, the director now directly owns 64,223 shares in the company, valued at $748,197.95. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Joseph Ciaffoni sold 64,821 shares of Collegium Pharmaceutical stock in a transaction on Thursday, November 7th. The shares were sold at an average price of $18.77, for a total value of $1,216,690.17. Following the completion of the transaction, the chief executive officer now owns 242,276 shares of the company’s stock, valued at $4,547,520.52. The disclosure for this sale can be found here. Over the last quarter, insiders sold 111,927 shares of company stock valued at $1,957,475. 8.08% of the stock is owned by company insiders.

A number of large investors have recently bought and sold shares of the stock. Janus Henderson Group PLC boosted its stake in Collegium Pharmaceutical by 19.1% during the second quarter. Janus Henderson Group PLC now owns 4,323,555 shares of the specialty pharmaceutical company’s stock valued at $56,855,000 after buying an additional 693,812 shares during the period. BlackRock Inc. boosted its stake in Collegium Pharmaceutical by 7.1% during the second quarter. BlackRock Inc. now owns 2,488,479 shares of the specialty pharmaceutical company’s stock valued at $32,724,000 after buying an additional 165,018 shares during the period. Vanguard Group Inc. boosted its stake in Collegium Pharmaceutical by 1.5% during the second quarter. Vanguard Group Inc. now owns 1,571,474 shares of the specialty pharmaceutical company’s stock valued at $20,665,000 after buying an additional 22,883 shares during the period. Rice Hall James & Associates LLC boosted its stake in Collegium Pharmaceutical by 5.8% during the second quarter. Rice Hall James & Associates LLC now owns 1,260,690 shares of the specialty pharmaceutical company’s stock valued at $16,578,000 after buying an additional 69,549 shares during the period. Finally, Cortina Asset Management LLC boosted its stake in Collegium Pharmaceutical by 81.0% during the second quarter. Cortina Asset Management LLC now owns 509,701 shares of the specialty pharmaceutical company’s stock valued at $6,703,000 after buying an additional 228,035 shares during the period. 91.31% of the stock is owned by institutional investors.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, develops and commercializes various products for patients suffering from pain. It provides DETERx platform technology that is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods of abuse and misuse, including chewing, crushing, heating, and injecting.

Read More: Channel Trading

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Collegium Pharmaceutical (NASDAQ:COLL)

Receive News & Ratings for Collegium Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.